|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Capital District Health Authority, Canada |
|---|---|
| Information provided by: | Capital District Health Authority, Canada |
| ClinicalTrials.gov Identifier: | NCT00317070 |
Purpose
The primary objective of this study is to evaluate the efficacy and tolerability of the intravesical cocktail and its comparison with intravesical DMSO in a controlled trial for the treatment of painful bladder syndrome including interstitial cystitis.
| Condition | Intervention | Phase |
|---|---|---|
|
Interstitial Cystitis Bladder Diseases |
Drug: dimethyl sulfoxide Drug: IC Cocktail |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) |
| Enrollment: | 10 |
| Study Start Date: | April 2006 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
DMSO: Active Comparator
Intravesical installation
|
Drug: dimethyl sulfoxide
intravesical installation 50 ml
|
| Cocktail: Experimental |
Drug: IC Cocktail
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Canada, Nova Scotia | |
| Dept. of Urology, Queen Elizabeth II Health Sciences Center | |
| Halifax, Nova Scotia, Canada, B3H 3A7 | |
| Principal Investigator: | Jerzy Gajewski, MD, FRCSC | Capital District Health Authority |
More Information
| Responsible Party: | Capital District Health Authority, Canada ( Jerzy B Gajewski ) |
| Study ID Numbers: | CDHA010 |
| Study First Received: | April 20, 2006 |
| Last Updated: | May 8, 2009 |
| ClinicalTrials.gov Identifier: | NCT00317070 History of Changes |
| Health Authority: | Canada: Health Canada |
|
PBS/IC Painful bladder syndrome including Interstitial cystitis |
|
Cystocele Disease Antioxidants Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urinary Bladder Diseases Cystitis Protective Agents |
Cryoprotective Agents Pharmacologic Actions Cystitis, Interstitial Dimethyl Sulfoxide Pathologic Processes Urologic Diseases Syndrome Free Radical Scavengers |